Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer

366 patients fully resected from a Dukes B2 or C colorectal cancer were ran domised to receive 6 courses of systemic chemotherapy comprising either 5-f luorouracil (5 FU) alone (arm A : 450 mg/m(2)/day - 5/21 days) or combined folinic acid (FOL) and 5 FU (arm B : respectively 200 mg/m(2) racemic form or 100 mg/m(2)-l-form and 370 mg/m(2)/day - 5/21 days). 173 patients had al so been initially randomised to receive one course of intraportal chemother apy just after surgery or no portal treatment. Oral levamisole (150 mg/day; 3 days every other week) was given to all patients for one year. A signifi cantly higher incidence of leuco-granulocytopenia was observed in the arm A (5 FU alone) inducing more frequent dose delays and adaptations as well as levamisole's withdrawal. Then dose-intensities and dose-intensity products were lower in this arm but the does intensity expressed in mg/m(2)/week re mained higher (631 +/- 107 vs 557 +/- 99; p < 0.001). The median follow-up in the study was 4.5 years. Relapse free (RFS) and overall survivals (OAS) were prolonged in the 5 FU alone group peculiarly in those patients who had not been randomised for portal treatment. Curves diverged progressively wi th longer follow-up (at 8 years; RFS in arm A : 67-71 % vs 59-53 % in arm B ; OAS in arm A : 72-74 % vs 56-46 % in arm B). Patients suffering from a co lon or a Dukes C cancer benefited the most from the treatment with 5 FU alo ne. The results are discussed in the light of other recent adjuvant trials. Well dosed 5 FU over a short period of time without folinic acid may be a valuable and inexpensive adjuvant treatment for colorectal cancer. Levamiso le may no longer be recommended in this setting.